You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,821,057


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,821,057
Title:Anti-IL-6 antibody for use in the treatment of cachexia
Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient\'s survivability or quality of life will preferably be improved.
Inventor(s): Smith; Jeffrey T. L. (Bellevue, WA), Latham; John A. (Seattle, WA), Litton; Mark (Seattle, WA), Schatzman; Randall (Redmond, WA)
Assignee: ALDERBIO HOLDINGS LLC (Las Vegas, NV)
Application Number:14/672,543
Patent Claims:1. A method for treating or inhibiting cachexia in a patient receiving chemotherapy, comprising administering to the patient an effective amount of an anti-IL-6 antibody or an IL-6 binding antibody fragment comprising the variable light (V.sub.L) chain CDR1 of SEQ ID NO:4, CDR2of SEQ ID NO:5 and CDR3 of SEQ ID NO:6, and the variable heavy (V.sub.H) chain CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:8 or 120, and CDR3 of SEQ ID NO:9, wherein the patient has been diagnosed with cancer and the chemotherapy agent is selected from VEGF antagonists, EGFR antagonists, platins, taxols, irinotecan,5-fluorouracil, gemcitabine, leucovorin, steroids, cyclophosphamide, melphalan, vinca alkaloids, vinblastine, mustines, tyrosine kinase inhibitors, radiotherapy, sex hormone antagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF antagonists, IL-1 antagonists, interleukins, IL-12R antagonists, Toxin conjugated monoclonal antibodies, tumor antigen specific monoclonal antibodies, Erbitux.TM., Avastin.TM., Pertuzumab, anti-CD20 antibodies, Rituxan.RTM., ocrelizumab, ofatumumab, DXL625, Herceptin.RTM., or any combination thereof.

Details for Patent 9,821,057

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 10/26/2009 ⤷  Try a Trial 2029-11-24
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 04/01/2011 ⤷  Try a Trial 2029-11-24
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 08/20/2020 ⤷  Try a Trial 2029-11-24
Genentech, Inc. PERJETA pertuzumab Injection 125409 06/08/2012 ⤷  Try a Trial 2029-11-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.